Geoffrey Mackay - Feb 2, 2022 Form 4 Insider Report for AVROBIO, Inc. (AVRO)

Role
President & CEO, Director
Signature
/s/ Christopher Gerry, Attorney-in-Fact for Geoffrey MacKay
Stock symbol
AVRO
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 04:22 PM
Previous filing
Jun 14, 2021
Next filing
Jun 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVRO Stock Option (Right to Buy) Award $0 +405K $0.00 405K Feb 2, 2022 Common Stock 405K $1.84 Direct F1
transaction AVRO Stock Option (Right to Buy) Award $0 +329K $0.00 329K Feb 2, 2022 Common Stock 329K $1.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period.